I recall Donna referring to this dose as the best dose on...

I recall Donna referring to this dose as the best dose on balance of safety, efficacy, duration of effect with DMOAD characteristics. I suppose until the adrenal vacuole in the rodent is knocked on the head, there is still an argument that it isn’t as safe as we believe. In happier times, I can recall members of the hotcopper community feeling that the USA FDA were almost mean to us for not overlooking this as it’s a common physiological phenomenon in rodents. Therefore we may consider ourselves a little unlucky there. But given the scale that this drug could have…. seems reasonable to address. Anyway…. That adrenal meeting is in Q1.

Then we go to the FDA for a protocol review. That should give the 2mg dose the green light.

remember the phase 3 program is “adaptive” and has fast track designation…. So hopefully with all the data collated, Donna can get the job done for us.

I understand your point about a Global OA deal or US/Europe…. I dare say if the right deal presented Paul
would sign up. But I also think a China and LATAM deal would suffice and sure up our balance sheet.

I just feel there are a few 1m hurdles to overcome, first.